RDNT

As of 2026-09-10, RDNT scores 38out of 100 on QNTM’s five-factor quantitative model, a low conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. RDNT trades at $74.28, 99% above the band ceiling.

RDNT scores 38 out of 100 on QNTM's five-factor model — a low-conviction reading — at 38 the factor profile is among the weaker names in the universe. Its strongest factor is momentum at 56 (solid), where price trend and relative strength are working in its favor, followed by quality at 40. The weakest is sentiment at 22, where sentiment signals are working against it. Among Healthcare stocks it sits in the lower 20% of Healthcare names by composite.

On valuation, RDNT is priced near the top of its recent range — the rich end on the model's valuation read. The blended composite before the macro overlay was 40. Same-sector names the model rates nearby include HALO, THC, TGTX.

This is a descriptive factor read on RDNT, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where RDNT sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for RDNT runs $24.86–$37.39. Current price $74.28 sits 99% above the band ceiling. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-10.